This medicine has provisional approval in Australia to treat COVID-19 in adults who are at increased risk of progression to hospitalisation or death. This approval has been granted on the basis of short-term efficacy and safety data. Evidence of efficacy

Medical Information
Australia
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Australian Healthcare Professionals. Would you like to proceed?

January 5, 2022

This medicine has provisional approval in Australia to treat COVID-19 in adults who are at increased risk of progression to hospitalisation or death. This approval has been granted on the basis of short-term efficacy and safety data. Evidence of efficacy and safety from ongoing trials continues to be gathered and assessed.